USPTO serial 97861879
BPG BIO
Reviewed by CopyMark Law Group
Status 734Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- GALLOWAY, JAMILLA ESPY
- Law office
- —
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with BPG BIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,246*
Plus Government fees of $600
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Framingham, MA, US
Waltham, MA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Lori J. Shyavitz, Esq.
Lori J. Shyavitz, Esq. MCCARTER & ENGLISH, LLP265 FRANKLIN STREETBOSTON, MA 02110-3113United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in the diagnosis, prevention, management and treatment of metabolic, viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, opthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related conditions, diseases and disorders; Diagnostic preparations for medical and veterinary use; Pharmaceutical preparations for wounds; Clinical medical reagents; Diagnostic kits comprised of medical reagents for medical and clinical use in disease testing, bodily fluid testing, biometric testing, cardiovascular testing, heart rate testing, organ function testing, hydration testing, and nutrition testing | ACTIVE | — |
| 009 | Downloadable computer software for compiling and analyzing scientific and medical data; Recorded computer software for compiling and analyzing scientific and medical data; Downloadable computer software for big data analytics, and for collecting and analyzing data in the field of healthcare; Recorded computer software for big data analytics, and for collecting and analyzing data in the field of healthcare; Downloadable computer software for use in accessing and importing data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications; Recorded computer software for use in accessing and importing data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications | ACTIVE | — |
| 042 | Pharmaceutical, scientific, medical, biopharmaceutical and biotechnology research and development; Drug discovery services; Pharmaceutical and biopharmaceutical drug development services; Providing medical and scientific research information in the field of medicine and pharmaceuticals; Medical research services in the field of cancer; Medical testing for scientific research purposes in the field of metabolic condition and disease, cancer, biomarkers, endocrinology diseases, central nervous system diseases and inflammatory disorders; Medical research featuring the identification and validation of disease related biomarkers; Data mining; Research and development in the field of biomarkers; Research and development in the fields of biomarker discovery and validation; Medical and scientific research in the field of biomarker discovery in cancer patients; Providing scientific information in the field of pharmaceuticals; Pharmaceutical and medical research in the field of outcomes research; Medical research featuring the identification and validation of disease related biomarkers for use in improved patient outcomes; Providing on-line, non-downloadable software applications to compile and analyze scientific and medical data; Software as a service (SAAS) services featuring software for big data analytics, and for collecting and analyzing data in the field of healthcare; Providing on-line, non-downloadable computer software for use in accessing and importing scientific and medical data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications; Platform as a service (PAAS) featuring computer software platforms for data collection, data analytics, data storage and data mining, for use in the field of healthcare | ACTIVE | — |
| 044 | Providing medical information in the field of medicine and pharmaceuticals; Medical services; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in the field of cancer research; Medical diagnostic, prognostic and theranostic screening and testing; Theranostic assessment of a disease or condition for medical purposes; Theranostic analysis services for medical purposes; Medical diagnostic and theranostic monitoring and reporting services; Health care services, namely, providing a database of diseases and the collection of disease data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of patient diagnostic, admissions, discharge, transfer (ADT), electronic health records (EHR), molecular, biomarker, genomic medicine, and clinical data including medication and laboratory values with systems for output of customized knowledge and information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Patient outcome analysis services, namely, providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses, treatments and therapies associated with a defined set of symptoms and evaluating patient records, disease markers and environmental factors to provide patients with information about possible diagnoses, treatments and therapies; Predictive modeling of data in the fields of medicine and healthcare, for medical diagnostic, prognostic and treatment purposes; Providing health information; Medical information; Providing health information, medical information, disease management information, and information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals, said information provided to others | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BPGbio Inc.
- Other trademarks owned by BPGbio Inc.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BPG BIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 13, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Oct 8, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Oct 8, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 7, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 7, 2026 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 7, 2026 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 7, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 10, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 9, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 9, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 9, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 10, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 10, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 9, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 9, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 20, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 20, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 20, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 8, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 8, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 9, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 13, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 13, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 24, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 9, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 26, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 26, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 26, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 26, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 12, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 21, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Apr 20, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 31, 2023 | NWAP | NEW APPLICATION ENTERED | — |